Holen Sie sich die Stockscreener-App
34.59
4.12%
1.37
Handel nachbörslich:
34.58
-0.01
-0.03%
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks - Contemporary Pediatrics
FDA accepts Pharvaris NDA for oral HAE attack treatment drug - Investing.com
Pharvaris wins FDA review for oral HAE attack treatment - Stock Titan
PHVSPharvaris NV Latest SEC Filings - Finviz
Pharvaris Insider Sold Shares Worth $1,331,496, According to a Recent SEC Filing - marketscreener.com
Pharvaris Insider Sold Shares Worth $2,695,452, According to a Recent SEC Filing - marketscreener.com
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells 37,600 Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan - Stock Titan
Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares - Stock Titan
PHVS (NASDAQ) insiders executed multiple 10b5-1 sales in 2026 - Stock Titan
PHVS insiders (PHVS) list option exercise and multiple 10b5-1 sales in June 2026 - Stock Titan
Form 144: Hans H. Schikan 10b5-1 sales listed for PHVS (PHVS) - Stock Titan
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Form 144 Pharvaris N.V. For: 29 June By Investing.com - Investing.com South Africa
Pharvaris (PHVS) exec’s 10b5-1 option exercise and 4,600-share sale - Stock Titan
Pharvaris (PHVS) director’s 2,400-share Rule 10b5-1 stock sale detailed - Stock Titan
Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan - Stock Titan
PHVS (NASDAQ: PHVS) 10b5-1 sales logged; Form 144 for 6,888 shares - Stock Titan
PHVS holders execute multiple 10b5-1 sales (NASDAQ: PHVS) - Stock Titan
8,300-share option exercise; multiple 10b5-1 sales reported (PHVS) - Stock Titan
Price to book forward of Pharvaris N.V. – GETTEX:9EN - TradingView
Liquidity Mapping Around (PHVS) Price Events - Stock Traders Daily
PHVS Gains 2.13% as Biotech Sentiment Brightens – Key Levels to WatchValue Factor - dars.gov.et
Price to book forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Enterprise value to revenue forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Pharvaris N.V. Actuals & Estimates (NASDAQ:PHVS) - TradingView
Enterprise value to revenue forward of Pharvaris N.V. – LS:A2QNWS - TradingView
Price to sales forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Price to book forward of Pharvaris N.V. – LS:A2QNWS - TradingView
Enterprise value to EBITDA forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Price to earnings forward of Pharvaris N.V. – LS:A2QNWS - TradingView
[144] Pharvaris N.V. SEC Filing - Stock Titan
Enterprise value to EBIT forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM - TipRanks
[6-K] Pharvaris N.V. Current Report (Foreign Issuer) | PHVS SEC FilingForm 6-K - Stock Titan
PHVS Forecast — Price Target — Prediction for 2027 - TradingView
Pharvaris N.V. Actuals & Estimates (FWB:9EN) - TradingView
Form 144 Pharvaris N.V. For: 25 June By Investing.com - Investing.com India
9EN Forecast — Price Target — Prediction for 2027 - TradingView
PHVS (NASDAQ) director 10b5-1 sales include 29,070 shares on 04/30/2026 - Stock Titan
PHVS (NASDAQ: PHVS) insider plans to sell 15,000 shares after option exercise - Stock Titan
PHVS Maintained by Morgan Stanley -- Price Target Raised to $46. - GuruFocus
PHVS (NASDAQ) reports director/entity 10b5-1 sales on April 22–30, 2026 - Stock Titan
PHVS (NASDAQ) files Form 144: 2,300 shares tied to option exercise - Stock Titan
Robust RAPIDe-3 Deucrictibant Data Might Change The Case For Investing In Pharvaris (PHVS) - Sahm
Pharvaris (PHVS) CMO sells 300 shares in scheduled 10b5-1 trade - Stock Titan
Pharvaris (PHVS) Is Up 6.0% After Strong Phase 3 Oral HAE Data With Novel Endpoint Introduction - Sahm
PHVS Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Clinical ProgressRevenue Miss Report - dars.gov.et
PHVS reports 10b5-1 sales and option exercise (PHVS) - Stock Titan
Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pharvaris (PHVS) CEO Modig sells 2,291 shares in planned Rule 10b5-1 trades - Stock Titan
Pharvaris NV (PHVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pharvaris NV (PHVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pharvaris NV (PHVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pharvaris NV (PHVS) Institutional Confidence - TradingKey
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pharvaris NV (PHVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):